Some patients with renal cell carcinoma (RCC) are able to have the tumor surgically removed from the kidney during an operation called nephrectomy. However, if the tumor is determined to be of a high stage, there is a greater risk of recurrence.
Pazopanib is a drug approved for the treatment of RCC which has spread to other parts of the body. The purpose of this study is to see if pazopanib can help reduce the risk of recurrence in patients with localized or locally advanced RCC who had nephrectomy.
Pazopanib is a tablet that is taken orally (by mouth). Patients will be randomly assigned to receive pazopanib or a placebo (sugar pill).